Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.

[1]  D. D. de Jong,et al.  Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study , 2019, Journal of Crohn's & colitis.

[2]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[3]  F. Carrat,et al.  Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. , 2018, Gastroenterology.

[4]  G. Kaplan,et al.  Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[5]  S. Hanauer,et al.  Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. , 2018, Gastroenterology.

[6]  D. Rubin,et al.  Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. , 2018, Inflammatory bowel diseases.

[7]  R. Eliakim,et al.  Association of Vedolizumab Level, Anti‐Drug Antibodies, and &agr;4&bgr;7 Occupancy With Response in Patients With Inflammatory Bowel Diseases , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  F. Carrat,et al.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease , 2017, JAMA.

[9]  A. Cohen,et al.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  T. Wyant,et al.  A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab , 2017, Clinical Pharmacokinetics.

[11]  G. Kaplan,et al.  Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study , 2017, Inflammatory bowel diseases.

[12]  C. Ponsioen,et al.  Suppression of anti‐drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[13]  J. Ludvigsson,et al.  Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) , 2017, Scandinavian journal of gastroenterology.

[14]  A. Ananthakrishnan,et al.  Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab , 2017, Digestive Diseases and Sciences.

[15]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[16]  J. Gisbert,et al.  Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort , 2016, Inflammatory bowel diseases.

[17]  Dawn B. Beaulieu,et al.  Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab , 2016, Inflammatory bowel diseases.

[18]  D. Tanyingoh,et al.  Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[20]  J. Lewis,et al.  Sa1270 Efficacy of Vedolizumab With Concomitant Corticosteroid or Immunomodulator Use in Patients With Crohn's Disease From GEMINI 2 , 2015 .

[21]  R. Veenendaal,et al.  Influence of Combination Therapy with Immune Modulators on Anti-TNF Trough Levels and Antibodies in Patients with IBD , 2014, Inflammatory bowel diseases.

[22]  A. Cohen,et al.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. , 2014, Gastroenterology.

[23]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[24]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[25]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[26]  G. Lichtenstein.  Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response , 2013, Therapeutic advances in gastroenterology.

[27]  U. Kopylov,et al.  Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[29]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[30]  M. Lebwohl,et al.  Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies , 2011, The British journal of dermatology.

[31]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[32]  P. Rutgeerts,et al.  EDITOR’S QUIZ: GI SNAPSHOT , 2007, Gut.

[33]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[34]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[35]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[36]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[37]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[38]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[39]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[40]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[41]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[42]  Ulrich Klotz,et al.  Clinical Pharmacokinetics and Use of Infliximab , 2007, Clinical pharmacokinetics.

[43]  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .